Moh, Desmorys Raoul
Ntakpé, Jean-Baptiste
Gabillard, Delphine
Yayo-Emieme, Arlette Ahoubet
Badjé, Anani
Kouame, Gérard M.
d’Aquin, Toni Thomas
Danel, Christine
Anglaret, Xavier
Eholié, Serge P.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults
https://doi.org/10.1186/s12879-022-07082-2
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?
https://doi.org/10.1016/s0140-6736(13)61998-4
Quantiferon-TB Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High CD4 Count in Côte d'Ivoire, West Africa
https://doi.org/10.1371/journal.pone.0107245
Article History
Received: 7 October 2021
Accepted: 21 January 2022
First Online: 29 January 2022
Declarations
:
: The Temprano protocol was approved by the Côte d'Ivoire National Ethics Committee for Health Research and registered at Clinical Trials.gov (NCT00495651). Eligible patients provided written informed consent. The study was carried out in accordance with relevant national and international guidelines and regulations. The sponsor (Agence Nationale de Recherches sur le Sida et les hépatites virales) had no role in the conduct of the study or interpretation of the data.
: Not applicable.
: The authors declare that they have no competing interests.